Written by Arsalan Arif

The Dutch antibody shop Argenx SE (ARGX) is the latest biotech to join the growing IPO parade on Nasdaq [closing up 35% on the day. Yesterday's IPO by G1 Therapeutics was also a success closing the day up 10.67% above its initial price. 

The biotech raised $100 million from the sale of 5.9 million shares at $17 each and that reflects an increase of more than 2 million shares over what the company had initially planned to offer. Just a few weeks ago Argenx was shooting for a $75 million offering, hoping to attract investors to its antibody Fc engineering technologies...

Just a day ago [the Research Triangle Park, NC-based outfit,] G1 Therapeutics, Inc. (GTHX) raised $105 million, hitting the low mark in its range [by selling 7 million shares at $15 each.] 

[As mentioned in my article yesterday on G1 Therapeutics' IPO] the biotech has been closely focused on CDK 4/6.

• CEO Mark Velleca and the crew at G1 feel they have started down the path to developing CDK 4/6 drugs that they believe can do much better in tackling cancer than the first wave. Ibrance is closely linked with neutropenia, forcing physicians to give the drug on an intermittent schedule with time off to help patients handle the side effects.
• G1 believes its IV CDK 4/6 is a first-in-class contender that can supersede the frontrunners on the market and it has another therapy in the clinic that’s aimed at protecting the immune system from the ravages of chemotherapy, helping amplify chemo’s positive effects while blunting the side effects.

G1 Therapeutics' IPO followed a string of IPOs over the last month from Ovid Therapeutics Inc. (OVID) worth $75 million, Verona Pharma PLC (VRNA) hit $78 million, UroGen Pharma Ltd. (URGN) tucked in $58 million, ZymeWorks Inc. (ZYME) gained $59 million and BioHaven, (BHVN) with a rich haul of $168 million.

That comes to $643 million in gross proceeds over the past few weeks - and with that kind of money on the table, you should expect to see more CEOs dusting off their S-1s and F-1s.